IMA

ImageneBio Inc

Sep 16 • 04:00PM ET

8.52

-0.44 -4.97 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-7.64	Insider Own	24.25%	Shs Outstand	11.18M	Perf Week	-7.34%
Market Cap	95.21M	Forward P/E	-	EPS next Y	-3.32	Insider Trans	14.88%	Shs Float	8.47M	Perf Month	-40.04%
Enterprise Value	5.25M	PEG	-	EPS next Q	-0.98	Inst Own	9.70%	Short Float	0.12%	Perf Quarter	-49.67%
Income	-30.74M	P/S	-	EPS this Y	75.87%	Inst Trans	2.24%	Short Ratio	0.31	Perf Half Y	-45.83%
Sales	0.00M	P/B	0.30	EPS next Y	-12.35%	ROA	-21.68%	Short Interest	0.01M	Perf YTD	-56.73%
Book/sh	28.82	P/C	1.00	EPS next 5Y	20.62%	ROE	-23.76%	52W High	23.28 -63.42%	Perf Year	-58.26%
Cash/sh	8.55	P/FCF	-	EPS past 3/5Y	-2.47% -16.81%	ROIC	-26.11%	52W Low	7.95 7.11%	Perf 3Y	-86.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.36% 7.31%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	55.32%	Oper. Margin	-	ATR (14)	0.82	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.52	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	27.20	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.52	EPS Q/Q	79.85%	SMA20	-26.39%	Beta	0.46	Target Price	276.00
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	-39.55%	Rel Volume	3.01	Prev Close	8.96
Employees	10	LT Debt/Eq	0.02	Earnings	Aug 07	SMA200	-46.57%	Avg Volume	31.07K	Price	8.52
IPO	Mar 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	0.39% -	Trades		Volume	93,380	Change	-4.97%

Aug-05-25 09:55AM	Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade (Zacks)
Aug-01-25 04:15PM	ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-25-25 11:00AM	Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million (GlobeNewswire)

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bonita David P	Director	Jul 25 '25	Buy	29.90	83,611	2,499,969	287,885	Jul 30 04:51 PM
Stampacchia Otello	Director	Jul 25 '25	Buy	29.90	267,556	7,999,924	454,982	Jul 30 04:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMA

ImageneBio Inc

Upgrade your FINVIZ experience